Saner Esther, Nitsch Dorothea, Descoeudres Claude, Frey Felix J, Uehlinger Dominik E
Division of Nephrology/Hypertension, University of Bern, Freiburgstrasse, 3010 Bern - Inselspital, Switzerland. E-mail:
Nephrol Dial Transplant. 2005 Mar;20(3):604-10. doi: 10.1093/ndt/gfh674. Epub 2005 Jan 21.
Randomized, controlled comparisons between home haemodialysis (HHD) and centre haemodialysis (CHD) have not been performed to date. Reported survival benefits of HHD as compared with CHD from uncontrolled studies have been attributed largely to patient selection.
In order to minimize a selection bias, we have compared the outcome of our HHD and CHD patients with a nested case-cohort study. For each patient trained for HHD at our dialysis centre between 1970 and 1995 (n=103), a corresponding match was searched from the CHD patients by retrospective chart analysis. The pairs were matched for sex, age (+/-5 years), time of dialysis therapy onset (+/-2 years) and renal disease category. For 58 of the 103 HHD patients, a corresponding matched CHD patient was identified. Both treatment groups had the same mean age (50+/-13 years) at dialysis onset and were comparable with respect to the Khan comorbidity index, prevalence and duration of hypertension, smoking habits, history of myocardial infarction, stroke and peripheral vascular disease. In both groups, approximately 50% of the patients were transplanted during the observation period.
HHD patients were hospitalized less often and tended to have fewer operations as compared with CHD patients. Survival was significantly longer in HHD as compared with CHD. Five, 10 and 20 year survival rates were 93 (n=55 patients at risk), 72 (41) and 34% (11) with HHD and 64 (38), 48 (26) and 23% (4) with CHD, respectively. This survival difference persisted after adjusting for predictors of mortality, i.e. age at onset of dialysis, year of start of dialysis therapy and Khan comorbidity index.
HHD offers a cheap and valuable alternative to CHD, with no apparent disadvantages.
迄今为止,尚未进行过家庭血液透析(HHD)与中心血液透析(CHD)之间的随机对照比较。非对照研究报告称,与CHD相比,HHD具有生存优势,这在很大程度上归因于患者选择。
为了尽量减少选择偏倚,我们采用巢式病例对照研究比较了HHD和CHD患者的结局。对于1970年至1995年间在我们透析中心接受HHD培训的每位患者(n = 103),通过回顾性病历分析从CHD患者中寻找相应的匹配对象。配对条件为性别、年龄(±5岁)、透析治疗开始时间(±2年)和肾脏疾病类别。在103例HHD患者中,有58例找到了相应匹配的CHD患者。两个治疗组透析开始时的平均年龄相同(50±13岁),在汗氏合并症指数、高血压患病率和病程、吸烟习惯、心肌梗死、中风和外周血管疾病史方面具有可比性。在两组中,约50%的患者在观察期内接受了移植。
与CHD患者相比,HHD患者住院频率较低,手术次数也较少。与CHD相比,HHD患者的生存期明显更长。HHD患者的5年、10年和20年生存率分别为93%(n = 55例有风险患者)、72%(41例)和34%(11例),CHD患者分别为64%(38例)、48%(26例)和23%(4例)。在对死亡率预测因素(即透析开始年龄、透析治疗开始年份和汗氏合并症指数)进行调整后,这种生存差异仍然存在。
HHD是CHD的一种廉价且有价值的替代方案,没有明显缺点。